New horizons for targeted treatment of neuroendocrine tumors

Alberto Mangano, Georgios D. Lianos, Dimitrios H. Roukos, Sam E. Mason, Hoon Yub Kim, Gianlorenzo Dionigi

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)


Neuroendocrine tumors (NETs) are rare and heterogeneous tumors and there is a paucity of randomized clinical trials evaluating the different therapeutic strategies. Over recent years, some important molecular aspects have been investigated and multiple targeted therapies are currently available. One of the most promising targets for the therapy of NETs are the mTOR and angiogenic growth factor receptors. The advent of the inhibitors of the mTOR pathway, tyrosine kinase inhibitors and of somatostatin analogs have shown their efficacy in randomized clinical trials in terms of implementing clinical hormone-induced syndromes and progression-free survival of advanced NETs. This article summarizes the standard therapies and new perspectives in NET's treatment, which remains still very heterogeneous and little known entity.

Original languageEnglish
Pages (from-to)1059-1065
Number of pages7
JournalFuture Oncology
Issue number8
Publication statusPublished - 2016 Apr 1


  • carcinoid tumors
  • gastroenteropancreatic tumors
  • intertumor heterogeneity
  • intratumor heterogeneity
  • neuroendocrine tumors
  • targeted agents

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'New horizons for targeted treatment of neuroendocrine tumors'. Together they form a unique fingerprint.

Cite this